Acta Veterinaria et Zootechnica Sinica ›› 2025, Vol. 56 ›› Issue (5): 2466-2480.doi: 10.11843/j.issn.0366-6964.2025.05.042

• Clinical Veterinary Medicine • Previous Articles     Next Articles

Anti-inflammatory Effects of Chelidonium majus on IPEC-J2 Cells based on HPLC Fingerprint and Network Pharmacology

CHEN Zehan1(), ZHANG Ruoyi1, LIN Huiying1, ZENG Chunli1, LIN Fu2, LI Jian1,*()   

  1. 1. Fujian Key Laboratory of Traditional Chinese Veterinary Medicine and Animal Health, Fujian Agriculture and Forestry University, Fuzhou 350002, China
    2. Fujian Fude Agricultural Development Co., Ltd, Fuzhou 350000, China
  • Received:2024-07-01 Online:2025-05-23 Published:2025-05-27
  • Contact: LI Jian E-mail:2587583262@qq.com;lijian@fafu.edu.cn

Abstract:

Chelidonium majus can be used to treat various digestive and respiratory tract inflammations, but its mechanism of action is still unclear. This study predicts and analyzes the pharmacodynamic components and mechanisms of C. majus using fingerprint and network pharmacology. A total of 15 batches of C. majus fingerprint were established using HPLC and evaluated for similarity and principal component analysis. A network of active components and targets of C. majus was established using network pharmacology methods. The core anti-inflammatory components were analyzed, along with the core targets through protein interaction network analysis, followed by GO enrichment and KEGG enrichment analysis. The common peaks identified by fingerprint and the core components filtered by network pharmacology were intersected. The effects of C. majus on IPEC-J2 cell inflammation damage were studied using MTT and ELISA methods. The results showed that 12 out of 15 batches of C. majus had a similarity >0.9, with 21 common peaks identified, among which 6 were identified as protopine, chelidonine, coptisine, sanguinarine, berberine, and chelerythrine. Network pharmacology filtered out 8 core anti-inflammatory components, namely thalictriline, (s)-thalictroidine, (s)-tetrahydropalmatine, berberine, chelidonine, chelerythrine, oxidized sanguinarine, and (+/-)-thalicarpine. The intersection of these two sets of components was chelidonine, berberine, and chelerythrine. Referring to the regulations of the Chinese Pharmacopoeia, chelerythrine was selected for a study on its effect on IPEC-J2 cell inflammation. The study found that chelerythrine at concentrations of 2.5 to 10 μg·mL-1 could significantly improve cell survival rate, increase the content of IL-4 and IL-10, and decrease the content of NO, IL-1β, IL-6, IL-8, TNF-α, and TGF-β1. This study has established the HPLC fingerprint of C. majus and preliminarily revealed its pharmacodynamic components and mechanisms of action using network pharmacology methods. This provides a reference for its quality control and further development.

Key words: Chelidonium majus, fingerprint, network pharmacology, chelerythrine, anti-inflammatory

CLC Number: